Key facts
- Overture Life’s last known valuation is $150.0M (May 2021).
- It has raised $81.2M across 1 recorded rounds; the latest was Early Stage VC ($13.6M) in Dec 2017.
- Notable investors include Mana Ventures, Khosla Ventures, GV, Felicis, Octopus Ventures — 19 tracked in total.
- Overture Life has filed 2 Form Ds with the SEC since 2017, most recently Dec 2018 ($13.6M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Overture Life
Funding rounds
1 roundsAbout Overture Life
Developer of a reproduction automation technology designed to revolutionize embryology. The company's technology is focused on the automation of in vitro fertilization, involving the commercialization of devices for automated cryopreservation, and offers a product that offers embryo testing and freezing services, enabling clinics to know which embryos are viable before implantation as well as help people to make babies.
- Sector
- Healthcare
- HQ
- Alcobendas, Spain
- Founded
- 2017
- Employees
- 37
- Website
- overture.life/
- Ownership
- Privately Held (backing)
Overture Life doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Overture Life shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Overture Life in its N-PORT filings yet. We sweep new filings monthly.